Physicians' Academy for Cardiovascular Education

The known and unknown of SGLT2 inhibition in CKD

10' education - June 11, 2019 - ISN-WCN 2019 - Carol Pollock, MD - Sydney, Australia

ISN-WCN 2019 Prof. Carol Pollock explains why there may be benefits of SGLT2 inhibitors in patients with chronic kidney disease, and discusses knowledge gaps in this field.

Video navigation menu

  • The knowns and unknowns of SGLT2-i in CKD 00:40
  • Mechanisms of benefit of SGLT2-i in CKD 04:42
  • Reduced tubular Na+ reabsorption and tubuloglomerular feedback 05:57
  • Normalisation of impaired autophagy 08:33
  • Shift to a more efficient metabolic substrate 10:21
  • Reduced oxidative stress 15:15
  • Relative benefits of combined SGLT1/2 inhibitors 16:51

Educational information

This lecture by prof. Carol Pollock was part of a CME accredited symposium "SGLT2 inhibition in CKD: Discussing the key questions and evidence"

Faculty

Prof. Carol Pollock, MD, Nephrologist, The University of Sydney School of Medicine, Australia

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.

View our meeting report

Share this page with your colleagues and friends: